Pimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: Wnt/&bgr;‐catenin signaling pathway plays important role in colorectal cancer (CRC) and acts as a potential therapeutic target. Pimozide is a FDA‐approved clinical drug used to treat psychotic diseases and it has shown anticancer effect in some tumors partially via inhibition of Wnt/&bgr;‐catenin signaling pathway. This study aimed to investigate whether pimozide exerts anticancer effect on CRC and explore underlying mechanism. Methods and results: Pimozide was administrated to treat HCT116 and SW480 cells. Quantitative real‐time polymerase chain reaction and western blot were used to detect the expression of epithelial‐to‐mesenchymal transition markers and Wnt/&bgr;‐catenin signaling pathway‐related proteins. Cell proliferation and migration were measured by Cell Counting Kit‐8 and Transwell assays respectively. HCT116 and SW480 cells were subcutaneously injected into nude mice and when the volume of tumor grown measureable (approximately 100 mm3) animals were treated with vehicle saline or pimozide at a dose of 25 mg/kg·d by oral gavage and then tumor size was measured at 7, 14, 21 and 28 days post treatment. Pimozide dose‐dependently inhibited cell proliferation and migration in both HCT116 and SW480 cells, increased expression of E‐cadherin and decreased expression of N‐cadherin, vimentin and Snail. In addition, tumor growth was inhibited by pimozide in both HCT116 and SW480 xenografts in vivo. Expression of &bgr;‐catenin and Wnt target genes c‐Myc, cyclin D1, Axin 2 and survivin was reduced by pimozide treatment in both HCT 116 and SW480 cells. Conclusion: Pimozide exerts anticancer effect in CRC via inhibition of wnt/&bgr;‐catenin signaling pathway, suggesting it as a potential therapeutic drug for CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Cited by
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target
Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., Tao, Q., & Xu, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01616-7 · Cited by 857
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28
Metadata
- Authors
- Ren, Y., Tao, J., Jiang, Z., Guo, D., & Tang, J.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 209
- Pages
- 267-273
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W2887239058
- Cited by
- 45
- References
- 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.